MGO One Seven’s Relmada Therapeutics RLMD Stock Holding History

MGO One Seven’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$692K	Hold	100,000	–	–	0.01%	843
2026 Q1	$696K	Hold	100,000	–	–	0.01%	788
2025 Q4	$483K	Hold	100,000	–	–	0.01%	891
2025 Q3	$201K	Hold	100,000	–	–	﹤0.01%	1256
2025 Q2	$60K	Hold	100,000	–	–	﹤0.01%	1179
2025 Q1	$27K	Hold	100,000	–	–	﹤0.01%	1085
2024 Q4	$52K	Hold	100,000	–	–	﹤0.01%	1056
2024 Q3	$324K	Hold	100,000	–	–	0.01%	739
2024 Q2	$300K	Hold	100,000	–	–	0.01%	769
2024 Q1	$465K	Hold	100,000	–	–	0.02%	541
2023 Q4	$414K	Hold	100,000	–	–	0.02%	598
2023 Q3	$300K	Hold	100,000	–	–	0.02%	613
2023 Q2	$246K	Buy	+100,000	New	+$276K	0.02%	668

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MGO One Seven's RLMD Position: Q2 2026 in Review

MGO One Seven held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 100,000 shares worth $692K. The position accounts for 0.01% of the portfolio, ranked #843.

MGO One Seven first reported a position in RLMD in Q2 2023 and has held it in 13 quarters since. The position peaked at $696K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

MGO One Seven held 100,000 shares of Relmada Therapeutics worth $692K as of Q2 2026.
MGO One Seven left its Relmada Therapeutics share count unchanged in Q2 2026.
Relmada Therapeutics made up 0.01% of MGO One Seven's portfolio in Q2 2026, its #843 holding.
MGO One Seven first reported a position in Relmada Therapeutics in Q2 2023 and has held it in 13 quarters since.
MGO One Seven's Relmada Therapeutics position peaked at $696K in Q1 2026.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on MGO One Seven's 13F filing for Q2 2026, filed 31 Jul 2026.